{
    "eid": "2-s2.0-85046296879",
    "title": "Transcriptome analysis of ABCB1, ABCG2 and the BCL2/BAX ratio in refractory and relapsed canine lymphomas under treatment and rescue protocol",
    "cover-date": "2018-03-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Veterinary (all)",
            "@code": "3400",
            "@abbrev": "VETE"
        }
    ],
    "keywords": [
        "ABCB1",
        "ABCG2",
        "Bax",
        "Bcl2",
        "Relapsed/refractory lymphoma"
    ],
    "authors": [
        "Sirintra Sirivisoot",
        "Patharakrit Teewasutrakul",
        "Anudep Rungsipipat",
        "Sirikachorn Tangkawattana",
        "Somporn Techangamsuwan"
    ],
    "citedby-count": 1,
    "ref-count": 41,
    "ref-list": [
        "Development of multidrug resistance in a canine lymphoma cell line",
        "The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance",
        "Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: Sequential analysis and predictive ability in dogs with lymphoma",
        "P-glycoprotein expression in canine lymphoma: A relevant, intermediate model of multidrug resistance",
        "Quantification of MDR-1 gene expression in canine tissues by real-time reverse transcription quantitative polymerase chain reaction",
        "Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with lymphoma",
        "A longitudinal study of ABC transporter expression in canine multicentric lymphoma",
        "Cell signaling by receptor tyrosine kinases",
        "Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision",
        "Preliminary evidence for biologic activity of toceranib phosphate (Palladia((R))) in solid tumours",
        "Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia((R))) in tumour-bearing dogs: A phase i dose-finding study",
        "Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein",
        "A unified model of mammalian BCL-2 protein family interactions at the mitochondria",
        "Immunohistochemical expression study of proapoptotic BH3-only protein bad in canine nonneoplastic tissues and canine lymphomas",
        "Clinical role of bcl-2, bax, or p53 overexpression in peripheral T-cell lymphomas",
        "Mutation of p53 gene and its correlation with the clinical outcome in dogs with lymphoma",
        "Expression of apoptosis-regulating proteins bcl-2 and bax in lymph node aspirates from dogs with lymphoma",
        "Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma",
        "Pax5 as a potential candidate marker for canine B-cell lymphoma",
        "Development and application of multiple internal reference (housekeeper) gene assays for accurate normalisation of canine gene expression studies",
        "Caspase-3/-8/-9, bax and bcl-2 expression in the cerebellum, lymph nodes and leukocytes of dogs naturally infected with canine distemper virus",
        "Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR",
        "Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes",
        "Normalization of real-time quantitative reverse transcription-PCR data: A model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets",
        "Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper - Excel-based tool using pair-wise correlations",
        "MiRDeepFinder: A miRNA analysis tool for deep sequencing of plant small RNAs",
        "Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma",
        "Phase i dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies",
        "Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro",
        "Nilotinib (AMN107, tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/ pgp and ABCG2/BCRP/MXR transporters",
        "The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2",
        "Suitable reference genes for quantitative real-time rt-PCR in total RNA extracted from canine whole blood using the PAXgene system",
        "Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma",
        "Molecular profiling reveals prognostically significant subtypes of canine lymphoma",
        "Canine lymphomas: Association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival",
        "Mutational analysis of P-glycoprotein: Suppression of caspase activation in the absence of ATP-dependent drug efflux",
        "Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: A possible role of P-glycoprotein in lymphocyte survival",
        "T and b leukemic cell lines exhibit different requirements for cell death: Correlation between caspase activation, DFF40/DFF45 expression, DNA fragmentation and apoptosis in t cell lines but not in burkitt\u2019s lymphoma",
        "Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance",
        "Cluster analysis of apoptosis-associated bcl2 family proteins in diffuse large B-cell lymphomas. Relations with the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes",
        "THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60017165",
            "affilname": "Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017165",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Chulalongkorn University"
    ]
}